Skip to main content
  • Aficamten Reduces LVOT Gradients vs. Placebo in Obstructive HCM Patients – Phase II Study

    A next-in-class cardiac myosin inhibitor, aficamten, led to substantial reductions in left ventricular outflow tract (LVOT) gradients compared to placebo in patients with obstructive hypertrophic cardiomyopathy (oHCM), according to phase II study results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details